series-c-plus
Stage
3
Investors
About
ArgenX is a global immunology company focused on developing antibody therapies for severe autoimmune diseases, with a primary product, VYVGART, approved for treating generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Explore ArgenX's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.